VideoPodcastsPsychedelicsSmall Caps

What Investors Ought To Know About MindMed In 2025

By Shadd Dales On Dec 23, 2024

TDR Top 3 takeaways from the video on MindMed’s announcements, and plans for 2025:

MindMed achieved a significant milestone in 2024 by dosing the first patient in their Phase III Voyage Study of MM120.
The stock showed notable growth, starting the year at $3.30 and reaching $7 by December 2024, driven by key announcements like positive Phase 2B clinical results, FDA breakthrough therapy designation, and a $175 million funding round.
MindMed’s experienced executive team, including individuals with extensive FDA backgrounds, enhances the company’s credibility and positions it as an attractive target for big pharma buyouts.

MindMed is one of the leaders in the psychedelic industry space. Trading on the NASDAQ under the ticker symbol MNMD, MindMed is a clinical-stage biopharmaceutical company focused on developing novel treatments for brain health disorders. We’re taking a deep dive into the key announcements, stock performance, and challenges they’re facing to help offer insights for investors heading into 2025.

In December 2024, MindMed dosed its first patient in the Phase 3 Voyage Study for MM120, a pharmaceutical-grade LSD designed to treat Generalized Anxiety Disorder (GAD). Voyage is the first of two Phase 3 studies in GAD evaluating the efficacy and safety of MM120 versus a placebo. Earlier in 2024, the FDA granted breakthrough therapy designation for the drug based on positive Phase 2B clinical trial results. The Voyage study is a pivotal moment for MindMed and aims to enroll approximately 200 participants across the United States.

MNMD stock started the year at $3.30 and reached $7 by December 2024. The growth was driven by key announcements including the positive Phase 2B clinical results, FDA breakthrough therapy designation, and a $175 million funding round. Despite some dips due to market volatility and regulatory concerns, MindMed displayed resilience and closed the year on a high note.

Prospective investors may find MindMed’s leadership team is a critical strength, featuring individuals with extensive FDA experience. It also has strong financial backing and buyout potential. Shadd Dales explains what someone interested in investing ought to know, and the challenges MindMed will have to face in 2025.

AN – Sidebar Square

Shadd Dales

Shadd Dales is the Founder and President of The Dales Report and has an extensive background in the business media industry.

His work translates into over 15 years in mainstream media that included roles with BNN Bloomberg, CTV Properties and the iHeart Radio Network.

Shadd is considered one of the leading on air talents in both the cannabis and psychedelic space and has interviewed some of the most notable CEO names in the industry.

Shadd’s vision is to establish a content platform that is equivalent to a mainstream broadcast produced in a format that is relevant for today’s investor.